The patient survival was 4/6 (66.7%) with a graft survival of 3/6 (50%) at current follow-up. Case 1 has been doing well and been totally off
TPN 14 years after transplantation. Case 2 died 5 months due to Maraviroc datasheet overwhelming infection secondary to severe acute rejection. Case 3 died 6 weeks due to unknown etiology of cardiac failure. Cases 4 and 5 lost intestinal graft due to rejection 3 months and 10 years, respectively, after transplantation and are waiting for second transplantation. Case 6 received a blood-type incompatible graft from her father and experienced one episode of rejection 30 days after surgery. She is doing well at 9-month follow-up. Conclusion: Our experience suggests that living donor bowel transplantation is safe for the donors and is a valuable strategy in the treatment of irreversible intestinal failure. Careful patient selection and post-transplant care are essential for good long-term outcome. Key Word(s): 1. Transplantation; 2. Intestine; 3. Living donor; Presenting Author: LIANG ZHU Additional Authors: WEI SUN, YUNHONG WU, DEZHENG GONG, SHUZHUANG LI, BINHAO WANG, YA ZHANG, CHENGYAN CHU, XUMIN GUAN, FANG LI, LIMING WANG, ZHONG LIU, LILI GUAN, QIONG WU, BO YUAN, DEQIN YU, JINGZHOU MU, QIUYU CHEN, YUANHANG WU, ZIQI ZHAO, SHUHANG GAO, SIWEN LUO, SHUHAO ZHANG, YUAN ZOU Corresponding Author:
LIANG ZHU Affiliations: Adriamycin in vitro Department of Physiology, Dalian Medical University; College of Basic Medical Sciences; School of Public Health, Dalian Medical University; College of seven-year clinical medicine, Dalian Medical University; Department of Immunology, Dalian Medical University; General Surgery of the Second HospitalGeneral Surgery of the Second Hospital, Dalian Medical University; General Surgery of the First Affiliated Hospital, Dalian Medical University; Affiliated
Hospital, Peking University Health Science Center; College of five-year clinical medicine, Dalian Medical University Objective: Intestinal transplantation (IT) may eventually become PIK3C2G the definitive therapeutic modality for irreversible intestinal failure. However, the small intestinal graft injury limits the success and widespread use of IT. Glucagon-like peptide-2 (GLP-2) is an intestinal hormone that exhibits striking intestinotropic properties. For the first time, we used the proteomic approach to investigate the effect of GLP-2 (Glucagon Like Peptide-2) on normal intestinal mucosa growth and transplantation intestinal mucosa recovery, and clarify its mechanisms. Methods: 90 male Wistar rats of inbred line were divided into four groups according to the table of random number: normal intestine group (group a), GLP-2 intervention group (group b), intestinal transplantation group (group c), intestinal transplantation with GLP-2 intervention group (group d).